Clinical Trial Update: IDH1 Peptide Vaccine for Recurrent Grade II Glioma [Phase 1]

View source ↗

Summary

Phase 1 trial update of an IDH1 peptide vaccine for recurrent grade II glioma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Cancer
• Brain Neoplasm
• Brain Neoplasms Recurrent
• Brain Tumor
• Cancer of the Brain
• Glioma

Drugs mentioned

• IDH1 peptide vaccine (IDH1 peptide vaccine)

Snippet

Sponsor: Katy Peters, MD, PhD | Conditions: Brain Cancer, Brain Neoplasm, Primary | Phase 1 | Status: COMPLETED | Results posted: 2021-03-15